| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2024/06/15 | 03 : 47 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/06/15 | 00 : 00 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/06/14 | 22 : 30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/06/14 | 21 : 30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/06/06 | 21 : 30 | GlobeNewswire Inc. | Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/06/06 | 04 : 55 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/06/03 | 21 : 30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/05/30 | 06 : 29 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/05/21 | 06 : 05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/05/10 | 01 : 00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/05/09 | 21 : 30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/05/08 | 22 : 25 | GlobeNewswire Inc. | LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer” | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/04/25 | 04 : 25 | AllPennyStocks.com | Mixed Shelf Filing Gives Micro Cap Delayed Boost | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/03/28 | 04 : 35 | AllPennyStocks.com | Biotech Steals The Show Following Pre-Clinical Data Announcement | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/03/27 | 21 : 30 | GlobeNewswire Inc. | NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/03/21 | 21 : 30 | GlobeNewswire Inc. | LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/02/27 | 22 : 30 | GlobeNewswire Inc. | Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/02/26 | 22 : 30 | GlobeNewswire Inc. | LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2024/01/29 | 22 : 30 | GlobeNewswire Inc. | First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2023/11/13 | 22 : 30 | GlobeNewswire Inc. | LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2023/10/16 | 21 : 30 | GlobeNewswire Inc. | LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2023/10/09 | 21 : 30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2023/09/26 | 21 : 30 | GlobeNewswire Inc. | LIXTE Appoints Bas van der Baan as President and Chief Executive Officer | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2023/09/20 | 21 : 30 | GlobeNewswire Inc. | LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2023/07/21 | 05 : 05 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2023/07/18 | 21 : 00 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2023/07/17 | 21 : 30 | GlobeNewswire Inc. | Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2020/12/02 | 02 : 30 | GlobeNewswire Inc. | Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |
| 2020/12/01 | 05 : 52 | Business Wire | WestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc.... | NASDAQ:LIXTW | Lixte Biotechnology Holdings Inc |